371 related articles for article (PubMed ID: 10589362)
61. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab.
Bendtzen K; Geborek P; Svenson M; Larsson L; Kapetanovic MC; Saxne T
Arthritis Rheum; 2006 Dec; 54(12):3782-9. PubMed ID: 17133559
[TBL] [Abstract][Full Text] [Related]
62. Infliximab treatment for rheumatic disease: clinical and radiological efficacy.
St Clair EW
Ann Rheum Dis; 2002 Nov; 61 Suppl 2(Suppl 2):ii67-9. PubMed ID: 12379627
[TBL] [Abstract][Full Text] [Related]
63. Infliximab is associated with improvement in arterial stiffness in patients with early rheumatoid arthritis -- a randomized trial.
Tam LS; Shang Q; Li EK; Wang S; Li RJ; Lee KL; Leung YY; Ying KY; Yim CW; Kun EW; Leung MH; Li M; Li TK; Zhu TY; Chui RK; Tseung L; Yu SL; Kuan WP; Yu CM
J Rheumatol; 2012 Dec; 39(12):2267-75. PubMed ID: 22984272
[TBL] [Abstract][Full Text] [Related]
64. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.
Greenwald MW; Shergy WJ; Kaine JL; Sweetser MT; Gilder K; Linnik MD
Arthritis Rheum; 2011 Mar; 63(3):622-32. PubMed ID: 21360491
[TBL] [Abstract][Full Text] [Related]
65. Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial.
Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Shoji T; Sakamaki Y; van der Heijde D; Miyasaka N; Koike T
Mod Rheumatol; 2014 Sep; 24(5):715-24. PubMed ID: 24313916
[TBL] [Abstract][Full Text] [Related]
66. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: results through 2 years of the GO-FORWARD study extension.
Keystone EC; Genovese MC; Hall S; Miranda PC; Bae SC; Palmer W; Wu Z; Xu S; Hsia EC
J Rheumatol; 2013 Jul; 40(7):1097-103. PubMed ID: 23678153
[TBL] [Abstract][Full Text] [Related]
67. Rheumatoid arthritis: choice of antirheumatic treatment. Methotrexate first.
Prescrire Int; 2010 Feb; 19(105):30-4. PubMed ID: 20455343
[TBL] [Abstract][Full Text] [Related]
68. [Adalimumab (Humira)--efficacy in rheumatoid arthritis treatment with particular reference to working ability].
Grazio S
Reumatizam; 2008; 55(2):62-7. PubMed ID: 19024278
[TBL] [Abstract][Full Text] [Related]
69. Rescue of combination therapy failures using infliximab, while maintaining the combination or monotherapy with methotrexate: results of an open trial.
Ferraccioli GF; Assaloni R; Di Poi E; Gremese E; De Marchi G; Fabris M
Rheumatology (Oxford); 2002 Oct; 41(10):1109-12. PubMed ID: 12364628
[TBL] [Abstract][Full Text] [Related]
70. In early rheumatoid arthritis the combination of methotrexate and infliximab over 2 years reduces the progression of radiological lesions more than methotrexate alone.
Montecucco C
Clin Exp Rheumatol; 2005; 23(3):289-291. PubMed ID: 15971414
[No Abstract] [Full Text] [Related]
71. Retrospective clinical study of the efficacy of lower-dose methotrexate and infliximab therapy in patients with rheumatoid arthritis.
Wakabayashi H; Sudo A; Hasegawa M; Oka H; Uchida A; Nishioka K
Clin Rheumatol; 2010 Jun; 29(6):671-5. PubMed ID: 20204668
[TBL] [Abstract][Full Text] [Related]
72. Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study.
Haugeberg G; Conaghan PG; Quinn M; Emery P
Ann Rheum Dis; 2009 Dec; 68(12):1898-901. PubMed ID: 19386610
[TBL] [Abstract][Full Text] [Related]
73. Interstitial pneumonitis associated with infliximab therapy without methotrexate treatment.
Taki H; Kawagishi Y; Shinoda K; Hounoki H; Ogawa R; Sugiyama E; Tobe K
Rheumatol Int; 2009 Dec; 30(2):275-6. PubMed ID: 19373466
[TBL] [Abstract][Full Text] [Related]
74. Anti-tumor necrosis factor-alpha therapy in the ordinary clinical setting: Three-year effectiveness in patients with rheumatoid arthritis.
Kvalvik AG; Lefsaker L; Dyvik S; Brun JG
Joint Bone Spine; 2007 Dec; 74(6):606-11. PubMed ID: 17900958
[TBL] [Abstract][Full Text] [Related]
75. Regulation of serum chemokines following infliximab therapy in patients with rheumatoid arthritis.
Klimiuk PA; Sierakowski S; Domyslawska I; Chwiecko J
Clin Exp Rheumatol; 2006; 24(5):529-33. PubMed ID: 17181921
[TBL] [Abstract][Full Text] [Related]
76. Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial.
Stamm TA; Machold KP; Aletaha D; Alasti F; Lipsky P; Pisetsky D; Landewe R; van der Heijde D; Sepriano A; Aringer M; Boumpas D; Burmester G; Cutolo M; Ebner W; Graninger W; Huizinga T; Schett G; Schulze-Koops H; Tak PP; Martin-Mola E; Breedveld F; Smolen J
Arthritis Res Ther; 2018 Aug; 20(1):174. PubMed ID: 30092827
[TBL] [Abstract][Full Text] [Related]
77. The cost effectiveness of infliximab for severe treatment-resistant rheumatoid arthritis in the UK.
Barbieri M; Wong JB; Drummond M
Pharmacoeconomics; 2005; 23(6):607-18. PubMed ID: 15960556
[TBL] [Abstract][Full Text] [Related]
78. Evolution of imaging findings, laboratory and functional parameters in rheumatoid arthritis patients after one year of treatment with anti-TNF-α agents.
Detorakis EE; Magkanas E; Lasithiotaki I; Sidiropoulos P; Boumpas DT; Gourtsoyiannis N; Antoniou K; Raissaki M
Clin Exp Rheumatol; 2017; 35(1):43-52. PubMed ID: 27908307
[TBL] [Abstract][Full Text] [Related]
79. Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis.
Takeuchi T; Yamanaka H; Tanaka Y; Sakurai T; Saito K; Ohtsubo H; Lee SJ; Nambu Y
Mod Rheumatol; 2015; 25(6):817-24. PubMed ID: 25736355
[TBL] [Abstract][Full Text] [Related]
80. Persistent clinical response of infliximab therapy in patients with refractory rheumatoid arthritis, over a 3-year period.
Voulgari PV; Alamanos Y; Drosos AA
Curr Clin Pharmacol; 2006 Jan; 1(1):103-8. PubMed ID: 18666381
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
